News

Under the agreement, Sprint Bioscience licenses a PIP4k2a inhibitor program targeting tumor metabolism to the Company. Subsequently, the Company will have full control over further development and worldwide

The clinical hold was initiated after two patient deaths last week, which followed the recent addition of fludarabine to the pre-conditioning regimen. Juno has proposed to the FDA

The study’s objective was to investigate the safety and efficacy of several dose regimens for vobarilizumab monotherapy to support additional clinical development. Its primary endpoint was the proportion

The Egality trial focused on patients with moderate-to-severe chronic plaque-type psoriasis. The European Medicines Agency and the US Food and Drug Administration accepted for regulatory review of Sandoz

The companies will use avelumab, a PD-L1 checkpoint inhibitor, together with a platinum-based chemotherapy for women with locally advanced or metastatic disease with earlier untreated epithelial ovarian cancer.

Aprecia manufactures its products using its proprietary ZipDose technology platform, that utilizes three dimensional printing (3DP) to formulate fast melt pharmaceutical products, which incorporates significantly higher amounts of

Cx601 is a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally. Under the terms of the deal, TiGenix will receive an upfront cash payment of €25M, milestones

Under the new multi-year enterprise deal, Medidata Clinical Cloud will be incorporated into all clinical trials across Hanmi’s drug development programs. Hanmi has more than doubled its investment

All commercial manufacturing of RIZAPORT will take place at IntelGenx’ new state-of-the-art manufacturing facility in Canada. Full details of the financial terms of the agreement were not disclosed.